Literature DB >> 10715266

Dose-dependence of 4-aminopyridine plasma concentrations and electrophysiological effects in dogs : potential relevance to ionic mechanisms in vivo.

S Nattel1, C Matthews, E De Blasio, W Han, D Li, L Yue.   

Abstract

BACKGROUND: Previous investigators have administered 4-aminopyridine (4AP) to dogs to evaluate the role of transient outward current (I(to)) in vivo; however, plasma concentrations of 4AP were not measured, and it is therefore uncertain which cardiac ion channels were blocked at the concentrations achieved. METHODS AND
RESULTS: We applied high-performance liquid chromatography to measure 4AP concentrations produced by intravenous 4AP administration to dogs. A previously described dose regimen produced plasma concentrations that increased during the maintenance infusion but never exceeded 250 micromol/L and caused significant mortality. Whole-cell patch-clamp experiments on isolated canine myocytes showed that even the maximum 4AP concentrations achieved in vivo failed to alter ventricular I(to) and had very small effects on atrial I(to); however, concentrations achieved in vivo had a strong inhibitory effect on the dog ultrarapid delayed rectifier (I(Kur.d)), present only in atrial cells. We designed a loading and maintenance infusion regimen to produce stable 4AP plasma concentrations. At concentrations in the range of 25 and 50 micromol/L, 4AP had no effect on ventricular refractory period but increased atrial refractoriness significantly, consistent with the results of voltage clamp studies.
CONCLUSIONS: The interpretation of previous studies using intravenous 4AP administration to inhibit I(to) in dogs in vivo needs to be reevaluated in light of the fact that the infusion regimens used produce plasma concentrations that are inadequate to affect ventricular I(to). Our findings also support the concept that selective inhibition of ultrarapid delayed rectifier current can prolong atrial refractory periods without affecting ventricular refractoriness.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715266     DOI: 10.1161/01.cir.101.10.1179

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  20 in total

Review 1.  Novel pharmacological targets for the rhythm control management of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2011-08-17       Impact factor: 12.310

2.  Atrial-selective prolongation of refractory period with AVE0118 is due principally to inhibition of sodium channel activity.

Authors:  Alexander Burashnikov; Hector Barajas-Martinez; Dan Hu; Eyal Nof; Jonathan Blazek; Charles Antzelevitch
Journal:  J Cardiovasc Pharmacol       Date:  2012-06       Impact factor: 3.105

3.  How Do Atrial-Selective Drugs Differ From Antiarrhythmic Drugs Currently Used in the Treatment of Atrial Fibrillation?

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  J Atr Fibrillation       Date:  2008

4.  Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart.

Authors:  Nathalie Gaborit; Sabrina Le Bouter; Viktoria Szuts; Andras Varro; Denis Escande; Stanley Nattel; Sophie Demolombe
Journal:  J Physiol       Date:  2007-05-03       Impact factor: 5.182

5.  Effect of 4-Aminopyridine on Action Potential Parameters in Isolated Dog Purkinje Fibers.

Authors:  George Thomas; Brian Klatt; Andrew Blight
Journal:  Arch Drug Inf       Date:  2010-03

Review 6.  New pharmacological strategies for the treatment of atrial fibrillation.

Authors:  Alexander Burashnikov; Charles Antzelevitch
Journal:  Ann Noninvasive Electrocardiol       Date:  2009-07       Impact factor: 1.468

7.  Inhibition of HERG K+ current and prolongation of the guinea-pig ventricular action potential by 4-aminopyridine.

Authors:  J M Ridley; J T Milnes; Y H Zhang; H J Witchel; J C Hancox
Journal:  J Physiol       Date:  2003-05-09       Impact factor: 5.182

8.  Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.

Authors:  Alexander Burashnikov; José M Di Diego; Andrew C Zygmunt; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circulation       Date:  2007-09-04       Impact factor: 29.690

9.  The plateau outward current in canine ventricle, sensitive to 4-aminopyridine, is a constitutive contributor to ventricular repolarization.

Authors:  A Sridhar; D N Q da Cunha; V A Lacombe; Q Zhou; J J Fox; R L Hamlin; C A Carnes
Journal:  Br J Pharmacol       Date:  2007-08-13       Impact factor: 8.739

10.  Atrial-selective sodium channel block as a strategy for suppression of atrial fibrillation.

Authors:  Alexander Burashnikov; José M Di Diego; Andrew C Zygmunt; Luiz Belardinelli; Charles Antzelevitch
Journal:  Ann N Y Acad Sci       Date:  2008-03       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.